Imunon, Inc. will hold a conference call on May 12, 2026, to report its first quarter financial results and update investors on the clinical development of IMNN-001, its DNA-based immunotherapy for advanced ovarian cancer. The company is advancing Phase 3 trials of IMNN-001, which aims to boost cancer-fighting molecules at tumor sites. This update follows successful Phase 2 trials showing improved survival rates, positioning IMNN-001 as a promising treatment option. Investors can join the call via phone or webcast to learn more about the company’s progress and future plans.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to repurchase shares worth up to DKK 3.1 billion by February 2027. The company has repurchased 4,432,353 shares at an average price of DKK 250.27, totaling abo...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed public dealings involving the purchase and sale of 52,929 ordinary shares on July 24, 2026. The trades occurred within a price range of 941 to 956.75 per share. There w...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed public dealings in the company's ordinary shares on July 24, 2026. The bank purchased 2,326,617 shares at prices between 280 and 280.5 pence and ...
LEPAS, a mid-to-premium NEV brand under Chery Auto, has introduced the LEPAS L8 PHEV globally, showcasing advanced hybrid technology, smart driving features, and refined design inspired by the agility and resilience of a leopard. The vehicle offers a...
Chery Auto's NEV brand LEPAS has introduced the LEPAS L8 PHEV globally, combining advanced hybrid technology with intelligent driving features and sophisticated design. Inspired by the precision and resilience of top athletes, the vehicle features a ...
